Immucell (ICCC) Common Equity (2010 - 2026)
Immucell's (ICCC) quarterly Common Equity came in at $27.1 million in Q4 2025, down 1.68% YoY from $27.5 million in Q4 2024, and down 9.21% on a QoQ basis from $29.8 million in Q3 2025.
Immucell (ICCC) Common Equity (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Common Equity data on file, last reported at $27.1 million in Q4 2025.
- Quarterly Common Equity fell 1.68% year-over-year to $27.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.1 million (down 1.68% YoY) and the FY2025 annual result came in at $27.1 million, down 1.68% from the prior year.
- Common Equity declined to $27.1 million in Q4 2025, from $29.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $33.2 million in Q1 2022 to a low of $23.5 million in Q2 2024.
- A 5-year average of $28.9 million and a median of $28.6 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity declined 18.66% — and 2025, when it increased 27.34%.
- Tracing ICCC's Common Equity over 5 years: stood at $32.6 million in 2021, then dropped by 6.74% to $30.4 million in 2022, then slipped by 17.73% to $25.0 million in 2023, then increased by 10.1% to $27.5 million in 2024, then declined by 1.68% to $27.1 million in 2025.
- The last three Common Equity figures came in at $27.1 million (Q4 2025), $29.8 million (Q3 2025), and $29.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 9.79 Bn |
| 10 | Immucell | 91.37 Mn | 82.51 Mn | 2.44 Mn | 31.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.37 Mn |
| Dec 31, 2025 | 27.06 Mn |
| Sep 30, 2025 | 29.80 Mn |
| Jun 30, 2025 | 29.87 Mn |
| Mar 31, 2025 | 28.99 Mn |
| Dec 31, 2024 | 27.52 Mn |
| Sep 30, 2024 | 26.41 Mn |
| Jun 30, 2024 | 23.46 Mn |
| Mar 31, 2024 | 24.64 Mn |
| Dec 31, 2023 | 24.99 Mn |
| Sep 30, 2023 | 26.01 Mn |
| Jun 30, 2023 | 26.86 Mn |
| Mar 31, 2023 | 28.16 Mn |
| Dec 31, 2022 | 30.38 Mn |
| Sep 30, 2022 | 31.98 Mn |
| Jun 30, 2022 | 32.55 Mn |
| Mar 31, 2022 | 33.15 Mn |
| Dec 31, 2021 | 32.58 Mn |
| Sep 30, 2021 | 32.46 Mn |
| Jun 30, 2021 | 32.27 Mn |